Literature DB >> 12044480

Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat.

M Marti1, R Guerrini, L Beani, C Bianchi, M Morari.   

Abstract

Intracerebral microdialysis was employed in awake freely moving rats to investigate the effects of nociceptin/orphanin FQ receptor ligands on glutamate extracellular levels in the substantia nigra pars reticulata. Nociceptin/orphanin FQ, ineffective at 0.1 microM, induced a prolonged stimulation of nigral glutamate levels at 1 and 10 microM (mean effect of 137+/-9 and 167+/-13%, respectively, of basal values). These effects were prevented by the novel nociceptin/orphanin FQ receptor antagonist [Nphe(1)]nociceptin/orphanin FQ(1-13)NH(2) (100 and 300 microM, respectively) but not by the non-selective opioid receptor antagonist naloxone (10 microM). [Nphe(1)]nociceptin/orphanin FQ(1-13)NH(2) (100 microM) inhibited by itself glutamate outflow (maximal reduction to 71+/-4%) while naloxone was ineffective. The nociceptin/orphanin FQ receptor ligand [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin/orphanin FQ(1-13)NH(2) also facilitated glutamate outflow at 10 microM (mean effect of 145+/-10%). Intranigral perfusion with tetrodotoxin (1 microM) or with the dopamine D(2) receptor antagonist raclopride (1 microM), failed to affect basal glutamate output and prevented the facilitatory effect of nociceptin/orphanin FQ (10 microM). However, perfusion with the GABA(A) receptor antagonist bicuculline (10 microM) increased local glutamate extracellular levels by itself and attenuated the effect of the peptide. Our data suggest that nociceptin/orphanin FQ increases glutamate extracellular levels in the substantia nigra pars reticulata via activation of nociceptin/orphanin FQ receptors located on non-glutamatergic, possibly dopaminergic and GABAergic, neuronal elements.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044480     DOI: 10.1016/s0306-4522(02)00050-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  14 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

2.  Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat.

Authors:  Daina Economidou; Andrea Cippitelli; Serena Stopponi; Simone Braconi; Stefano Clementi; Massimo Ubaldi; Rèmi Martin-Fardon; Friedbert Weiss; Maurizio Massi; Roberto Ciccocioppo
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

3.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

Review 4.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

7.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

8.  Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Authors:  Matteo Marti; Flora Mela; Carlo Veronesi; Remo Guerrini; Severo Salvadori; Mauro Federici; Nicola B Mercuri; Anna Rizzi; Gianfranco Franchi; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

9.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

10.  NeuroAIDS, drug abuse, and inflammation: building collaborative research activities.

Authors:  Joan W Berman; Monica J Carson; Linda Chang; Brian M Cox; Howard S Fox; R Gilberto Gonzalez; Glen R Hanson; Kurt F Hauser; Wen-Zhe Ho; Jau-Shyong Hong; Eugene O Major; William F Maragos; Eliezer Masliah; Justin C McArthur; Diane B Miller; Avindra Nath; James P O'Callaghan; Yuri Persidsky; Christopher Power; Thomas J Rogers; Walter Royal
Journal:  J Neuroimmune Pharmacol       Date:  2006-11-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.